National Institutes of Health logo
NIH SBIR

NIH SBIR Phase II (Omnibus)

Funds United States small businesses advancing validated biomedical innovations through substantial full development execution.

OpenNational Institutes of HealthUnited States

The NIH SBIR Phase II Omnibus is the National Institutes of Health's primary non-dilutive R&D execution grant for U.S. small businesses that have completed or can demonstrate Phase I-equivalent feasibility work. Issued under activity code R44, Phase II awards are capped at $2,045,816 in total costs and cover one to three years of full research and development — typically prototype construction, an…

Continuation of a successful Phase I project from the same NIH institute or center. Application must demonstrate Phase I milestone completion and a credible path to commercialization.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Multiple per year
Next deadlineiThe next date applications are due. Rolling means you can apply any time.5 Sept 2026
Decision timeiTypical time from the deadline to the funder's decision.36 weeks
Project durationiHow long the funded work is expected to run.1–24 months
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.$440M

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 22 Jul 2026Source: grants.nih.gov